{"id":59195,"date":"2026-03-10T16:43:47","date_gmt":"2026-03-10T08:43:47","guid":{"rendered":"https:\/\/flcube.com\/?p=59195"},"modified":"2026-03-10T16:43:48","modified_gmt":"2026-03-10T08:43:48","slug":"sicagenes-sg12-aso-wins-nmpa-approval-antisense-oligonucleotide-targets-hepatitis-b-functional-cure","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59195","title":{"rendered":"SicaGene&#8217;s SG12 ASO Wins NMPA Approval \u2013 Antisense Oligonucleotide Targets Hepatitis B Functional Cure"},"content":{"rendered":"\n<p><strong>SicaGene (Beijing) Biotechnology Co., LTD<\/strong> announced that <strong>SG12 injection<\/strong>, a <strong>self-developed antisense oligonucleotide (ASO)<\/strong>, has received <strong>NMPA clinical trial approval<\/strong> for the treatment of <strong>chronic hepatitis B (CHB)<\/strong>. The drug, designed to be <strong>complementary to key HBV mRNA sequences<\/strong>, effectively <strong>inhibits viral protein synthesis<\/strong>\u2014specifically <strong>hepatitis B surface antigen (HBsAg)<\/strong>\u2014with the goal of achieving <strong>functional clinical cure<\/strong> through HBsAg reduction or clearance. The milestone validates SicaGene&#8217;s <strong>next-generation oligonucleotide platform<\/strong> and positions the <strong>veteran team<\/strong> (with <strong>BeOne and Ionis<\/strong> pedigree) to address the <strong>250+ million global CHB population<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>National Medical Products Administration (NMPA)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial authorization (IND)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>SG12 injection<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Antisense oligonucleotide (ASO) \u2013 next-generation single-stranded<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Complementary binding to HBV mRNA \u2192 inhibits viral protein synthesis<\/td><\/tr><tr><td><strong>Primary Target<\/strong><\/td><td>Hepatitis B surface antigen (HBsAg)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Chronic hepatitis B (CHB)<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>SicaGene (Beijing) Biotechnology Co., LTD<\/td><\/tr><tr><td><strong>Team Pedigree<\/strong><\/td><td>Veterans from BeOne, Ionis (oligonucleotide R&amp;D, clinical, industrialization)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>9\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>SG12 Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Architecture<\/strong><\/td><td>Single-stranded antisense oligonucleotide<\/td><\/tr><tr><td><strong>Target Sequence<\/strong><\/td><td>Key HBV mRNA sequences (complementary design)<\/td><\/tr><tr><td><strong>Mechanism of Action<\/strong><\/td><td>\u2022 Binds to HBV mRNA<br>\u2022 Blocks translation of viral proteins<br>\u2022 Specifically reduces HBsAg synthesis<\/td><\/tr><tr><td><strong>Therapeutic Goal<\/strong><\/td><td>Functional cure: HBsAg reduction\/clearance \u2192 restoration of innate immune response<\/td><\/tr><tr><td><strong>Delivery<\/strong><\/td><td>Injection formulation (likely subcutaneous or intravenous)<\/td><\/tr><tr><td><strong>Platform<\/strong><\/td><td>Next-generation oligonucleotide chemistry (enhanced stability, potency, tissue distribution)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Functional Cure Rationale:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HBsAg as Barrier:<\/strong> Persistent HBsAg induces immune tolerance; clearance required to reactivate host anti-HBV immunity<\/li>\n\n\n\n<li><strong>ASO Advantage:<\/strong> Direct mRNA targeting vs. nucleos(t)ide analogs (viral suppression only); potential for finite treatment duration<\/li>\n\n\n\n<li><strong>Combination Strategy:<\/strong> SG12 + pegylated interferon or therapeutic vaccine may enhance cure rates<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Market Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Global CHB Burden<\/strong><\/td><td>296 million chronic infections; 820,000 annual deaths from cirrhosis\/HCC<\/td><\/tr><tr><td><strong>Current Standard<\/strong><\/td><td>Nucleos(t)ide analogs (entecavir, tenofovir) \u2013 viral suppression, not cure; lifelong therapy<\/td><\/tr><tr><td><strong>Functional Cure Gap<\/strong><\/td><td>&lt;1% spontaneous HBsAg clearance; huge unmet need for finite therapies<\/td><\/tr><tr><td><strong>ASO Competition<\/strong><\/td><td>Vir Biotechnology (VIR-2218), Ionis (bepirovirsen), Arrowhead (ARO-HBV) in Phase II\/III<\/td><\/tr><tr><td><strong>China Market<\/strong><\/td><td>90 million CHB patients; government priority for curative therapies; domestic innovation incentivized<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-dynamics\">Competitive Dynamics<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Product<\/th><th>Mechanism<\/th><th>Status<\/th><th>SG12 Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>GSK\/Vir<\/strong><\/td><td>Bepirovirsen (Ionis)<\/td><td>ASO targeting all HBV RNAs<\/td><td>Phase III<\/td><td>First-to-market potential; SG12 next-gen chemistry may improve efficacy\/tolerability<\/td><\/tr><tr><td><strong>Arrowhead<\/strong><\/td><td>ARO-HBV (JNJ-3989)<\/td><td>siRNA targeting HBV transcripts<\/td><td>Phase II<\/td><td>RNAi vs. ASO mechanism; combination approaches converging<\/td><\/tr><tr><td><strong>Assembly Bio<\/strong><\/td><td>Vebicorvir<\/td><td>Core inhibitor + ASO combos<\/td><td>Phase II<\/td><td>Small molecule + oligonucleotide combinations<\/td><\/tr><tr><td><strong>SicaGene<\/strong><\/td><td><strong>SG12<\/strong><\/td><td><strong>Next-gen ASO targeting HBsAg<\/strong><\/td><td><strong>Phase I-ready<\/strong><\/td><td><strong>China-developed; veteran Ionis\/BeOne team; potential cost\/manufacturing advantage<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-outlook\">Development Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Timeline<\/th><th>Objectives<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase I<\/strong><\/td><td>2026-2027<\/td><td>Safety, tolerability, PK\/PD; HBsAg reduction kinetics; dose-ranging<\/td><\/tr><tr><td><strong>Phase II<\/strong><\/td><td>2027-2029<\/td><td>Efficacy in CHB patients; combination with NA backbone; functional cure rates<\/td><\/tr><tr><td><strong>Phase III<\/strong><\/td><td>2029-2031<\/td><td>Head-to-head or non-inferiority vs. bepirovirsen; China NDA; global partnership<\/td><\/tr><tr><td><strong>Global Strategy<\/strong><\/td><td>2028+<\/td><td>U.S.\/EU IND filing; Fast Track designation; licensing discussions with multinational pharma<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-value\">Strategic Value<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Team Differentiation:<\/strong> Ionis\/BeOne veterans bring 20+ years oligonucleotide drug development experience; de-risked platform execution<\/li>\n\n\n\n<li><strong>China Advantage:<\/strong> Domestic regulatory pathway; potential for NRDL inclusion; government support for hepatitis elimination goals<\/li>\n\n\n\n<li><strong>Platform Expandability:<\/strong> ASO technology applicable to other viral diseases (HDV, HPV) and genetic disorders<\/li>\n\n\n\n<li><strong>Partnership Potential:<\/strong> Attractive asset for global pharma seeking China market entry + oligonucleotide manufacturing capabilities<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, functional cure achievement, and competitive positioning for SG12. Actual results may differ due to ASO delivery challenges, viral escape mechanisms, and competitive dynamics in the hepatitis B curative therapy race.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>SicaGene (Beijing) Biotechnology Co., LTD announced that SG12 injection, a self-developed antisense oligonucleotide (ASO), has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":59197,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,4642,89],"class_list":["post-59195","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-sicagene-biotechnology","tag-viral-hepatitis"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>SicaGene&#039;s SG12 ASO Wins NMPA Approval \u2013 Antisense Oligonucleotide Targets Hepatitis B Functional Cure - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"SicaGene (Beijing) Biotechnology Co., LTD announced that SG12 injection, a self-developed antisense oligonucleotide (ASO), has received NMPA clinical trial approval for the treatment of chronic hepatitis B (CHB). The drug, designed to be complementary to key HBV mRNA sequences, effectively inhibits viral protein synthesis\u2014specifically hepatitis B surface antigen (HBsAg)\u2014with the goal of achieving functional clinical cure through HBsAg reduction or clearance. The milestone validates SicaGene&#039;s next-generation oligonucleotide platform and positions the veteran team (with BeOne and Ionis pedigree) to address the 250+ million global CHB population.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59195\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SicaGene&#039;s SG12 ASO Wins NMPA Approval \u2013 Antisense Oligonucleotide Targets Hepatitis B Functional Cure\" \/>\n<meta property=\"og:description\" content=\"SicaGene (Beijing) Biotechnology Co., LTD announced that SG12 injection, a self-developed antisense oligonucleotide (ASO), has received NMPA clinical trial approval for the treatment of chronic hepatitis B (CHB). The drug, designed to be complementary to key HBV mRNA sequences, effectively inhibits viral protein synthesis\u2014specifically hepatitis B surface antigen (HBsAg)\u2014with the goal of achieving functional clinical cure through HBsAg reduction or clearance. The milestone validates SicaGene&#039;s next-generation oligonucleotide platform and positions the veteran team (with BeOne and Ionis pedigree) to address the 250+ million global CHB population.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59195\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-10T08:43:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-10T08:43:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1005.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59195#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59195\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"SicaGene&#8217;s SG12 ASO Wins NMPA Approval \u2013 Antisense Oligonucleotide Targets Hepatitis B Functional Cure\",\"datePublished\":\"2026-03-10T08:43:47+00:00\",\"dateModified\":\"2026-03-10T08:43:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59195\"},\"wordCount\":591,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59195#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1005.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"SicaGene Biotechnology\",\"Viral hepatitis\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59195#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59195\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59195\",\"name\":\"SicaGene's SG12 ASO Wins NMPA Approval \u2013 Antisense Oligonucleotide Targets Hepatitis B Functional Cure - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59195#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59195#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1005.webp\",\"datePublished\":\"2026-03-10T08:43:47+00:00\",\"dateModified\":\"2026-03-10T08:43:48+00:00\",\"description\":\"SicaGene (Beijing) Biotechnology Co., LTD announced that SG12 injection, a self-developed antisense oligonucleotide (ASO), has received NMPA clinical trial approval for the treatment of chronic hepatitis B (CHB). The drug, designed to be complementary to key HBV mRNA sequences, effectively inhibits viral protein synthesis\u2014specifically hepatitis B surface antigen (HBsAg)\u2014with the goal of achieving functional clinical cure through HBsAg reduction or clearance. The milestone validates SicaGene's next-generation oligonucleotide platform and positions the veteran team (with BeOne and Ionis pedigree) to address the 250+ million global CHB population.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59195#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59195\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59195#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1005.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1005.webp\",\"width\":1080,\"height\":608,\"caption\":\"SicaGene's SG12 ASO Wins NMPA Approval \u2013 Antisense Oligonucleotide Targets Hepatitis B Functional Cure\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59195#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SicaGene&#8217;s SG12 ASO Wins NMPA Approval \u2013 Antisense Oligonucleotide Targets Hepatitis B Functional Cure\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"SicaGene's SG12 ASO Wins NMPA Approval \u2013 Antisense Oligonucleotide Targets Hepatitis B Functional Cure - Insight, China&#039;s Pharmaceutical Industry","description":"SicaGene (Beijing) Biotechnology Co., LTD announced that SG12 injection, a self-developed antisense oligonucleotide (ASO), has received NMPA clinical trial approval for the treatment of chronic hepatitis B (CHB). The drug, designed to be complementary to key HBV mRNA sequences, effectively inhibits viral protein synthesis\u2014specifically hepatitis B surface antigen (HBsAg)\u2014with the goal of achieving functional clinical cure through HBsAg reduction or clearance. The milestone validates SicaGene's next-generation oligonucleotide platform and positions the veteran team (with BeOne and Ionis pedigree) to address the 250+ million global CHB population.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59195","og_locale":"en_US","og_type":"article","og_title":"SicaGene's SG12 ASO Wins NMPA Approval \u2013 Antisense Oligonucleotide Targets Hepatitis B Functional Cure","og_description":"SicaGene (Beijing) Biotechnology Co., LTD announced that SG12 injection, a self-developed antisense oligonucleotide (ASO), has received NMPA clinical trial approval for the treatment of chronic hepatitis B (CHB). The drug, designed to be complementary to key HBV mRNA sequences, effectively inhibits viral protein synthesis\u2014specifically hepatitis B surface antigen (HBsAg)\u2014with the goal of achieving functional clinical cure through HBsAg reduction or clearance. The milestone validates SicaGene's next-generation oligonucleotide platform and positions the veteran team (with BeOne and Ionis pedigree) to address the 250+ million global CHB population.","og_url":"https:\/\/flcube.com\/?p=59195","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-10T08:43:47+00:00","article_modified_time":"2026-03-10T08:43:48+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1005.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59195#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59195"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"SicaGene&#8217;s SG12 ASO Wins NMPA Approval \u2013 Antisense Oligonucleotide Targets Hepatitis B Functional Cure","datePublished":"2026-03-10T08:43:47+00:00","dateModified":"2026-03-10T08:43:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59195"},"wordCount":591,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=59195#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1005.webp","keywords":["Clinical trial approval \/ initiation","SicaGene Biotechnology","Viral hepatitis"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59195#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59195","url":"https:\/\/flcube.com\/?p=59195","name":"SicaGene's SG12 ASO Wins NMPA Approval \u2013 Antisense Oligonucleotide Targets Hepatitis B Functional Cure - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=59195#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=59195#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1005.webp","datePublished":"2026-03-10T08:43:47+00:00","dateModified":"2026-03-10T08:43:48+00:00","description":"SicaGene (Beijing) Biotechnology Co., LTD announced that SG12 injection, a self-developed antisense oligonucleotide (ASO), has received NMPA clinical trial approval for the treatment of chronic hepatitis B (CHB). The drug, designed to be complementary to key HBV mRNA sequences, effectively inhibits viral protein synthesis\u2014specifically hepatitis B surface antigen (HBsAg)\u2014with the goal of achieving functional clinical cure through HBsAg reduction or clearance. The milestone validates SicaGene's next-generation oligonucleotide platform and positions the veteran team (with BeOne and Ionis pedigree) to address the 250+ million global CHB population.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59195#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59195"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=59195#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1005.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1005.webp","width":1080,"height":608,"caption":"SicaGene's SG12 ASO Wins NMPA Approval \u2013 Antisense Oligonucleotide Targets Hepatitis B Functional Cure"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59195#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"SicaGene&#8217;s SG12 ASO Wins NMPA Approval \u2013 Antisense Oligonucleotide Targets Hepatitis B Functional Cure"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1005.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59195"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59195\/revisions"}],"predecessor-version":[{"id":59198,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59195\/revisions\/59198"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/59197"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59195"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59195"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}